Press releases
- Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
Key statistics
As of last trade Seres Therapeutics Inc (1S9:BRN) traded at 0.767, 0.00% above its 52-week low of 0.767, set on Jun 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.767 |
---|---|
High | 0.767 |
Low | 0.767 |
Bid | 0.652 |
Offer | 0.685 |
Previous close | 0.767 |
Average volume | -- |
---|---|
Shares outstanding | 151.45m |
Free float | 150.78m |
P/E (TTM) | -- |
Market cap | 171.14m USD |
EPS (TTM) | -0.6062 USD |
Data delayed at least 15 minutes, as of Jun 10 2024.
More ▼